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Abstract In 3–5 % of all cases of pancreatic ductal ade-
nocarcinoma (PDAC), hereditary factors influence etiol-
ogy. While surveillance of high-risk individuals may
improve the prognosis, this study describes two very dif-
ferent outcomes in patients with screen-detected lesions. In
2000, a surveillance program of carriers of a CDKN2A/
p16-Leiden-mutation consisting of annual MRI was initi-
ated. Patients with a suspected pancreatic lesion undergo
CT-scan and Endoscopic Ultrasound, and surgery is
offered when a lesion is confirmed. In 2015, two patients
with a screen-detected solid lesion were identified. In both
patients, lesions were visible on MRI and CT scan, while
the EUS was unremarkable. Surgical resection of the head
of the pancreas resulted in nearly fatal complications in the
first patient. This patient was shown to have a benign
lesion. In contrast, timely identification of an early cancer
in the second patient was accompanied by an uneventful
postoperative course. These cases underline the risks
inherent to a PDAC prevention program. All patients
should be fully informed about the possible outcomes
before joining a surveillance program.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is considered
one of the most aggressive forms of cancer. With PDAC
currently ranking fourth in terms of cancer-related deaths
in the United States [1], the prognosis will only improve if
the tumour can be detected and treated at an earlier stage.
Approximately 3–5 % of all patients with PDAC have a
genetic predisposition that results in an increased risk of
developing the tumor [2] and a substantial proportion of
these patients carry an underlying gene defect in CDKN2A/
p16-Leiden (Familial Atypical Multiple Mole Melanoma,
FAMMM syndrome), STK11 (Peutz-Jeghers syndrome),
the BRCA1/2 genes (Hereditary breast cancer) or one of the
MMR genes (Lynch syndrome) [3].
Because surveillance might improve the prognosis in
asymptomatic, high-risk individuals, in 2000 a surveillance
program for CDKN2A/p16-Leiden mutation carriers was
initiated at the department of Gastroenterology and Radi-
ology at the Leiden University Medical Centre (LUMC).
Surveillance consists of a yearly MRI, with an option for
EUS between two MRI scans. In cases where a pancreatic
lesion is suspected, an EUS and CT scan is performed in
order to confirm the presence of the lesion. If the lesion is
confirmed, pancreatic surgery is offered.
In this report, we describe surveillance and treatment
results for two CDKN2A/p16-Leiden patients with a screen-
detected lesion.
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Case 1
The first patient, a 55-year-old male with a CDKN2A/p16-
Leiden mutation, was referred to the Department of Gas-
troenterology and Hepatology at the Leiden University
Medical Centre in 2011 to discuss the option of pancreatic
surveillance. The patient had no known family history of
PDAC, and quit smoking in 2003.
The advantages and disadvantages of the surveillance
program were discussed with the patient before he gave
informed consent. In the summer of 2015, a solid 8 mm
lesion in the uncinate process of the pancreas was
detected by MRI (Fig. 1, upper panel). Retrospectively, a
small lesion was already visible on the previous MRI in
2014. The patient did not report any complaints and all
blood tests were normal, including CA19.9. Subsequent
CT scanning confirmed the presence of a solid 10 mm
lesion (Fig. 1, lower panel), whereas EUS was normal.
The patient was discussed by a multidisciplinary team
and resection was recommended because two of the three
imaging tools showed the presence of a solid lesion.
During surgical exploration, a small lesion was palpated
in the uncinate process of the pancreas and a pylorus-pre-
serving pancreaticoduodenectomy (PPPD) was performed.
Pathological examination of the surgical specimen showed
a 3 mm small area with sclerotic stroma and inflammation.
Amidst the sclerosis ductular proliferation, with focal
cribriform architecture was found. SMAD4 and p53
immunostaining was normal. Taking everything into
account it was concluded that there was no evidence of
(pre)cancer. A total of 23 lymph nodes were identified, all
of which were free of tumor.
One day after surgery the patient developed symptoms
suggesting leakage of the choledochojenunostomy. During re-
exploration the anastomosis was revised. Eight days after the
initial surgery, leakage of the pancreatico-jejunostomy led to a
re-laparotomy, with revision of the anastomosis with surgical
drains left in situ. Nine days after this intervention, the
patient’s condition deteriorated. Evidence for a new leakage
of the pancreatic anastomosis led to a completion pancreate-
ctomy. Eighteen weeks later, a retroperitoneal debridement of
necrosis in the former pancreatic bed was performed. Finally,
the patient developed a thoracic empyema and a subphrenic
abscess treated by thoracotomy and decortication. Following
the last intervention the patient recovered slowly and he was
discharged in a relatively good physical condition, 5 months
after the initial surgery. His diabetes is currently managed with
four daily doses of insulin.
Fig. 1 MRI (upper panel) and CT-scan (lower panel) of the pancreas in case 1
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Case 2
The second patient, a 50-year-old male with a CDKN2A/
p16-Leiden mutation, was referred to the department of
Gastroenterology and Hepatology. He underwent treatment
for melanoma at the ages of 36 and 40. He was asymp-
tomatic and he had never smoked. His father died of PDAC
at age 52. After discussion on the benefits and drawbacks,
the patient decided to participate in the surveillance pro-
gram (2012). An MRI scan in November 2015 showed a
possible 17 mm lesion with oedema in the head of the
pancreas (Fig. 2, upper panel). Retrospectively, a smaller
oedematous area was present at this site on the previous
MRI scan. CT scanning confirmed the presence of a solid
10 mm lesion in the same area (Fig. 2, lower panel), while
the EUS was unremarkable. Blood tests did not show any
abnormalities. The findings were discussed by the Leiden
multidisciplinary team and a PPPD was offered. Following
surgery, pathological examination of the surgical specimen
showed a 9 mm moderately differentiated PDAC, sur-
rounded by inflammation. The resection margins were free
(closed margin 0.3 mm facing the SMV) although there
was growth into the peripancreatic tissue. All 15 detected
lymph nodes were free of cancer. The patient recovered
well after surgery and did not encounter any complications.
He was discharged from hospital, in good physical condi-
tion, 8 days after initial surgery.
Discussion
These two cases clearly illustrate the dilemmas faced in the
surveillance of individuals at high-risk for PDAC. The first
patient experienced nearly fatal complications due to sur-
gery and was found to have a benign lesion. This is an
example of a worst-case scenario that may occur in this
type of surveillance program. The second patient, diag-
nosed shortly after the first case, had very similar imaging
findings, an uneventful course after surgery, and was
eventually shown to have an early cancer.
Several questions arise regarding these two patients:
(a) Did the findings, especially in the first patient, justify
surgery? (b) Could the benign nature of the lesion in the
first patient have been predicted? (c) How can the
surveillance programs be improved? (d) How can a dev-
astating course, as seen in the first patient, be prevented?
Regarding the first question, the two imaging techniques
(MRI and EUS) reportedly show a high sensitivity and
specificity [4], with MRI usually regarded as the best tool
to identify cystic lesions and EUS as the best technique for
the identification of solid lesions [5]. In both cases reported
here the presence of a solid lesion was shown on MRI and
CT, whereas the EUS was unremarkable. The fact that the
lesion was palpated in both patients during surgical
exploration confirmed the imaging findings and justified
surgery in view of the high risk of PDAC. Lesion growth is
a strong indicator for malignancy, but both patients showed
only slight lesional growth. Due to the rapid growth of
PDAC, another argument in favour of surgery is the short
window of time between the detection of a lesion and
development of metastatic disease [6].
In relation to the second issue, prediction of the benign
nature of a lesion, differentiation of benign and malignant
lesions by FNA biopsy might have been considered. In this
particular case no abnormalities were found on EUS, ruling
out EUS-guided biopsy. In retrospect, even if the lesion
had been visible on EUS, performance of an FNA biopsy
would not have been useful in decision-making in this case
because a negative FNA result does not exclude the pres-
ence of PDAC.
The second patient was diagnosed shortly after dis-
charge of the first patient. In view of the devastating course
in the first patient combined with the identification of a
benign lesion, we were very hesitant to offer surgery again.
However, based on the same arguments and after consul-
tation with international experts, surgery was offered. The
pathological findings following surgery in this case sub-
sequently confirmed that this was the right decision and
suggested that postponement of surgery would have
impaired the patient’s outcome.
Regarding the third question—improvement of surveil-
lance methods—this case report underlines the urgent need
for modification of screening methods, especially regarding
improvements in the sensitivity of MRI imaging of the
pancreas. Additional screening tools should also be
developed. At present, the value of the FDG-PET scan in
the detection of PDAC is questionable, because the mini-
mum size of lesions detectable by this technique is about
10 mm. However, developments in PET tracers that target
specific tumor biomarkers that occur as a consequence of
the CDKN2A/p16-Leiden defect could potentially lead to
earlier detection [7].
Another way to improve the surveillance program is the
use of circulating tumour markers. Slater et al. [8, 9]
reported promising results on the use of tumour markers,
including micro-RNAs 196a and b, LCN2, and TIMP1. In a
small pilot study, the application of proteomics allowed us
to differentiate between malignant and benign lesions [10].
However, these findings should be confirmed in larger
studies.
The final question concerns how the risks of serious
complications due to surgery can be minimized. Recent
studies suggest that mortality rates for pancreaticoduo-
denectomies procedure lie somewhere between 0.5 and
6 %, with a morbidity rate of up to 40 % [11, 12]. A recent
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decision model study showed that the possible benefits of a
surveillance program may be lost if the mortality rate is
slightly increased [13].
The only way to achieve the lowest possible mortality
and morbidity rates is to restrict prevention programs to
expert centres that carry out larges volume of pancreatic
surgeries. Moreover, it is very important to discuss the
advantages and disadvantages with a patient prior to their
participation in a surveillance program so that the patient is
fully aware of the risks. Advantages of the program
in CDKN2A/p16-Leiden mutation carriers are that more
tumours are identified at a resectable stage (75 % vs.
15–20 % in symptomatic patients) and that the prognosis
of patients with screen-detected tumours is better (5-year
survival is 24 %) than that of symptomatic patients
(5–7 %) [14].
Fig. 2 MRI (upper panel) and CT-scan (lower panel) of the pancreas in case 2
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Disadvantages include, (1) the surveillance program
cannot guarantee that PDAC is always detected at an early
and curable stage, (2) the screening protocol is burdensome
and may cause anxiety before and shortly after the
screening procedure, (3) there may be false positive and
false negative cases, and finally, (4) treatment consists of
major surgery, a pancreaticoduodenectomy or distal pan-
createctomy depending on the site of the tumor, all of
which are associated with substantial morbidity and
mortality.
These case reports illustrate the difficult decisions that
have to be made in high-risk individuals with a suspected
lesion in the pancreas. All involved physicians, together
with the patient, should be aware of all possible outcomes
of the intervention.
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